Log in to search using one of your social media accounts:

 

Gene editing – and what it really means to rewrite the code of life
We now have a precise way to correct, replace or even delete faulty DNA.Ian Sample explains the science, the risks and what the future may holdSo what is gene editing?Scientists liken it to the find and replace feature used to correct misspellings in documents written on a computer. Instead of fixing words, gene editing rewrites DNA, the biological code that makes up the instruction manuals of living organisms. With gene editing, researchers can disable target genes,correct harmful mutations, and change the activity of specific genes in plants and animals, including humans.What ’s the point?Much of the excitement aro...
Source: Guardian Unlimited Science - January 15, 2018 Category: Science Authors: Ian Sample Science editor Tags: Genetics Medical research Science Health Biology Source Type: news

Study reveals reversibility of Friedreich ’s ataxia in mice
Friedreich ’s ataxia is an inherited disease that causes damage to the nervous system and a loss of coordination that typically progresses to muscle weakness. It can begin causing symptoms in childhood or early adulthood and, over time, it can also lead to vision loss and diabetes.Scientists seeking a better understanding of the disease have tried for years to replicate the disease ’s symptoms and progression in laboratory mice, but until recently have been largely unsuccessful.Now, a team of UCLA researchers has recreated aspects of Friedreich ’s ataxia in mice and shown that many early symptoms of the d...
Source: UCLA Newsroom: Health Sciences - January 2, 2018 Category: Universities & Medical Training Source Type: news

UCLA researchers create skeletal muscle from stem cells
UCLA scientists have developed a new strategy to efficiently isolate, mature and transplant skeletal muscle cells created from human pluripotent stem cells, which can produce all cell types of the body. The findings are a major step toward  the development of a stem cell replacement therapy for muscle diseases including Duchenne muscular dystrophy, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.The study, which was published in the journal Nature Cell Biology, was led by senior author April Pyle, associate professor of microbiology, immunology and molecul...
Source: UCLA Newsroom: Health Sciences - December 18, 2017 Category: Universities & Medical Training Source Type: news

UCLA researchers create skeletal muscle from stem cells
(University of California - Los Angeles Health Sciences) UCLA scientists have developed a new strategy to efficiently isolate, mature and transplant skeletal muscle cells created from human pluripotent stem cells, which can produce all cell types of the body. The findings are a major step towards developing a stem cell replacement therapy for muscle diseases including Duchenne Muscular Dystrophy, which affects approximately 1 in 5,000 boys in the US and is the most common fatal childhood genetic disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2017 Category: International Medicine & Public Health Source Type: news

New 'checkpoint' model that could identify potential drugs to treat genetic disorders
(University of Bradford) A new 'checkpoint' model which can be used to identify potential treatments for genetic disorders such as cystic fibrosis and Duchenne muscular dystrophy (DMD) has been proposed by a team of Bradford scientists. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2017 Category: International Medicine & Public Health Source Type: news

Study: The medical community isn’t prepared for the looming pandemic of neurodegenerative diseases like Parkinson’s
(Natural News) Parkinson’s disease is the second most common neurodegenerative disease plaguing people today, with an estimated 1 million Americans are battling this illness – more than Lou Gehrig’s disease, muscular dystrophy and multiple sclerosis combined. Parkinson’s causes certain nerve cells in the brain to die, affecting movement and causing worsening tremors and stiffness. The... (Source: NaturalNews.com)
Source: NaturalNews.com - December 13, 2017 Category: Consumer Health News Source Type: news

Nationwide Children's gene therapy spinout raises $2.5M to test muscular dystrophy treatment
A gene therapy startup that spun out of Nationwide Children's Hospital six months ago has raised $2.5 million toward testing a treatment for a form of muscular dystrophy in patients. Myonexus Therapeutics Inc. is the fourth company to come out of gene therapy research at the Columbus hospital and the only one located in Central Ohio. CEO Michael Triplett and COO Bruce Halpryn are based in New Albany, and all of the contract research it sponsors takes place at Children's. “ The clinical impact… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 13, 2017 Category: Pharmaceuticals Authors: Carrie Ghose Source Type: news

Research reveals how diabetes in pregnancy affects baby ’s heart
Researchers at the  Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have discovered how high glucose levels — whether caused by diabetes or other factors — keep heart cells from maturing normally. Their findings help explain why babies born to women with diabetes are more likely to develop congenital heart disease.The study, which was led by Atsushi “Austin” Nakano, a UCLA associate professor of molecular, cell, and developmental biology and member of the Broad Stem Cell Research Center, was published today in the journal eLife.When developing heart cell...
Source: UCLA Newsroom: Health Sciences - December 12, 2017 Category: Universities & Medical Training Source Type: news

Voices: The Disabled Fl â neur
My diagnosis won ’ t keep me away from the city streets and the sweet energy that ’ s found there, even if someday I “ walk ” by dint of wheels. (Source: NYT Health)
Source: NYT Health - December 12, 2017 Category: Consumer Health News Authors: MARIAN RYAN Tags: Disabilities Muscular Dystrophy Wheelchairs Sidewalks Muscles Travel and Vacations Berlin (Germany) Source Type: news

Lab notes: raise a glass to your ear and hail the dinosaur swan
It lived about 71m years ago, had a swan-like neck, razor-sharp “killer claws” and a duck-billed snout and was about the size of a mallard, with a long tail and longer legs. This ‘very weird’ creature (not my words, that’s an actual scientist’s description there) is apparently anew species of amphibious dinosaur, discovered in a smuggled fossil from Mongolia. And to toast that exciting news, you ’ll need a really good glass of champagne - but how will you know whether you’ve been passed plonk or premier cru?According to researchers, the sound of the bubbles reveals all ... As...
Source: Guardian Unlimited Science - December 8, 2017 Category: Science Authors: Tash Reith-Banks Tags: Science Source Type: news

In lab research, scientists slow progression of a fatal form of muscular dystrophy
(Saint Louis University) Saint Louis University researchers report that a new drug reduces fibrosis (scarring) and prevents loss of muscle function in an animal model of Duchenne muscular dystrophy (DMD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 8, 2017 Category: International Medicine & Public Health Source Type: news

Adapted Crispr gene editing tool could treat incurable diseases, say scientists
New form of genetic engineering designed to boost gene activity could one day be used to overcome diseases such as diabetes and muscular dystrophyIncurable diseases such as diabetes and muscular dystrophy could be treated in future using a new form of genetic engineering designed to boost gene activity, according to scientists.The technique is an adapted version of the powerful gene editing tool called Crispr. While the original version of Crispr snips DNA in precise locations to delete faulty genes or over-write flaws in the genetic code, the modified form “turns up the volume” on selected genes.Continue readi...
Source: Guardian Unlimited Science - December 7, 2017 Category: Science Authors: Hannah Devlin Science correspondent Tags: Genetics Science Medical research Diabetes Biology Source Type: news

Researchers Advance Techniques To Change Gene Regulation And Treat Disease In Mice
Researchers were able to improve kidney function in mice with induced kidney damage, turn liver cells into insulin-producing pancreas cells in mice modeling type 1 diabetes, and improve muscle strength in animals with a muscular dystrophy-like condition. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 7, 2017 Category: Pharmaceuticals Authors: Ellie Kincaid, Forbes Staff Source Type: news

Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
Potential Registration Trial in Duchenne Muscular Dystrophy on Track to Initiate in First Quarter of 2018 Company to Host Conference Call and Webcast at 4:30 p.m. ET Today LOS ANGELES, Nov. 29, 2017 -- (Healthcare Sales & Marketing Network) -- Capri... Biopharmaceuticals, FDA Capricor Therapeutics, Duchenne muscular dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 29, 2017 Category: Pharmaceuticals Source Type: news

United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2017 -- (Healthcare Sales & Marketing Network) -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivi... Biopharmaceuticals, FDA, Licensing United Therapeutics, Adcirca, tadalafil, Duchenne muscular dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 20, 2017 Category: Pharmaceuticals Source Type: news

Duchenne muscular dystrophy sufferers cannot walk
Brothers Elliot Johnson, 14, and Henry, 11, from Pennsylvania fear they won't be able to walk again after the FDA pulled the drugs that have kept their rare muscle disorder under control. (Source: the Mail online | Health)
Source: the Mail online | Health - November 17, 2017 Category: Consumer Health News Source Type: news

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment
NEW YORK (Reuters) - Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary." (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Virtual gene editing startup to lease Cambridge lab after $40M round
The company, Exonics Therapeutics, said the Series A round will allow it to hire scientists to conduct preclinical research into a potential treatment for Duchenne muscular dystrophy. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 8, 2017 Category: American Health Authors: Max Stendahl Source Type: news

All babies in Europe should be screened for heart defects at birth
Only a few countries, including Poland, Ireland and Switzerland, currently recommend universal screening with pulse oximetry Related items fromOnMedica Blood test identifies high-risk lupus pregnancies Newborns screened for four additional genetic conditions Over 600,000 carry ‘sudden death’ gene fault The next generation of prenatal testing: let ’s proceed with caution Experts advise against screening for Duchenne Muscular Dystrophy (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 8, 2017 Category: UK Health Source Type: news

SLU researcher draws bulls eye around muscular dystrophy drug targets
(Saint Louis University) Scientist Francis M. Sverdrup, Ph.D., studies an inherited type of muscular dystrophy that typically begins with weakness in the face and shoulders before spreading to all skeletal muscles. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2017 Category: International Medicine & Public Health Source Type: news

Sarepta jumps into the CRISPR fray with Duke gene-editing pact
Cambridge-based Sarepta Therapeutics said Tuesday that it will seek to develop drugs for Duchenne muscular dystrophy using CRISPR/Cas9 gene-editing technology, jumping into an increasingly competitive but still uncertain field. Sarepta (Nasdaq: SRPT) said it had reached an agreement to exclusively license technology related to CRISPR/Cas9 from Duke University. Researchers there, led by Dr. Charles Gersbach, have shown that the technology can be used in mice to remove mutated parts of genes, or exons,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 31, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

FDA declines to approve PTC's Duchenne drug
(Reuters) - The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works. (Source: Reuters: Health)
Source: Reuters: Health - October 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA declines to approve PTC's Duchenne Muscular Dystrophy drug
(Reuters) - The U.S. Food and Drug Administration has declined to approve PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, saying an additional clinical trial would be needed to prove the drug works. (Source: Reuters: Health)
Source: Reuters: Health - October 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA rejects muscular dystrophy drug, says it doesn't work
U.S. regulators reject experimental drug for Duchenne muscular dystrophy. (Source: ABC News: Health)
Source: ABC News: Health - October 25, 2017 Category: Consumer Health News Tags: Health Source Type: news

Mom-and-pop drug developers: How these parents are funding a drug for their sons
Both of their sons have a version of muscular dystrophy that has no approved treatment and is slowly robbing the boys of control over their hip and shoulder muscles. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 18, 2017 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

C-Path and CDISC announce therapeutic area user guide for duchenne muscular dystrophy
(Critical Path Institute (C-Path)) C-Path and CDISC announce the availability of TAUG-DMD v1.0: a therapeutic area user guide that describes the most common clinical concepts relevant to Duchenne studies using the CDISC standard format, which allows datasets from different sources to be compared or combined for analysis. Data covered include genetic information, cardiac and respiratory data, as well as results from specific measurements of strength and function. Data standards are also being developed for a variety of functional assessments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 18, 2017 Category: International Medicine & Public Health Source Type: news

Chronic inflammation may improve drug delivery in MD patients
Researchers at Children's National Health System found chronic inflammation is vital in sustained delivery of a new treatment for Duchenne muscular dystrophy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 16, 2017 Category: Consumer Health News Source Type: news

Chronic inflammation may improve drug delivery in muscular dystrophy patients
Researchers at Children's National Health System found chronic inflammation is vital in sustained delivery of a new treatment for Duchenne muscular dystrophy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 16, 2017 Category: Consumer Health News Source Type: news

What's the next step for exon skipping therapies to treat duchenne muscular dystrophy?
(Mary Ann Liebert, Inc./Genetic Engineering News) A team of leading European clinicians and scientists presents a unique perspective on how to move forward in the development of exon skipping therapies to treat the severe muscle-wasting disease Duchenne Muscular Dystrophy (DMD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2017 Category: International Medicine & Public Health Source Type: news

Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress
Data Set the Stage for the Upcoming HOPE-2 Clinical Trial of CAP-1002 SAINT MALO, France, Oct. 4, 2017 -- (Healthcare Sales & Marketing Network) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), in its presentation today at the 22nd Annual International C... Regenerative Medicine Capricor Therapeutics, Duchenne muscular dystrophy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 4, 2017 Category: Pharmaceuticals Source Type: news

Armed with fresh trial data, Catabasis doubles down on Duchenne drug
Regrouping after a trial setback involving its lead drug for Duchenne muscular dystrophy, Cambridge-based Catabasis Pharmaceuticals is forging ahead with a late-stage study, touting new data on Wednesday hinting that the treatment can improve the lives of boys with the muscle-wasting disease. Catabasis (Nasdaq: CATB) previously announced in January that a Phase 2 study of the drug, called edasalonexent, had failed to meet its primary goal — significantly reducing leg muscle inflammation compared… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 4, 2017 Category: American Health Authors: Max Stendahl Source Type: news

'CRISPR-Gold' fixes Duchenne muscular dystrophy mutation in mice
(University of California - Berkeley) Scientists at the University of California, Berkeley, have engineered a new way to deliver CRISPR-Cas9 gene-editing technology inside cells and have demonstrated in mice that the technology can repair the mutation that causes Duchenne muscular dystrophy, a severe muscle-wasting disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 3, 2017 Category: International Medicine & Public Health Source Type: news

Nonviral CRISPR Delivery a Success
Researchers use gold nanoparticles to deliver CRISPR-Cas9 and correct a point mutation in a mouse model of Duchenne muscular dystrophy. (Source: The Scientist)
Source: The Scientist - October 2, 2017 Category: Science Tags: Daily News Source Type: news

PTC Therapeutics Duchenne drug may work, data inconclusive: FDA panel
(Reuters) - PTC Therapeutics Inc's experimental drug to treat Duchenne muscular dystrophy, a devastating degenerative disease that mostly affects young boys, may work but the company will need to do more work to prove it, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA pours cold water on PTC Therapeutics' Duchenne drug application
(Reuters) - PTC Therapeutics Inc has not supplied "persuasive" evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, a preliminary review by scientists at the U.S. Food and Drug Administration concluded. (Source: Reuters: Health)
Source: Reuters: Health - September 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Phrixus to study P-188 NF in Phase II trial to treat DMD
US-based Phrixus Pharmaceuticals is set to conduct a Phase II clinical trial of Poloxamer 188 NF (P-188 NF) for the treatment of non-ambulatory patients with Duchenne muscular dystrophy (DMD). (Source: Drug Development Technology)
Source: Drug Development Technology - September 17, 2017 Category: Pharmaceuticals Source Type: news

Santhera shares plummet after negative CHMP opinion
ZURICH (Reuters) - Swiss drugmaker Santhera's shares plunged nearly 60 percent in early trading on Friday, after a European panel recommended against approving one of its drugs to be used in patients with Duchenne muscular dystrophy (DMD). (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

University of Minnesota researchers replicate FSH muscular dystrophy in mice
(University of Minnesota) A new study published in the journal Nature Communications describes a breakthrough in research related to facioscapulohumeral muscular dystrophy (FSHD). The debilitating genetic disease -- which has no approved treatment -- affects an estimated 38,000 Americans and causes muscle degeneration. Scientists inserted into mice a gene called DUX4, which is believed to cause FSHD in humans. When they activated the gene in mice skeletal muscle cells, the animals developed a muscular dystrophy with key features of FSHD. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 15, 2017 Category: International Medicine & Public Health Source Type: news

This Is How Telethons Became a Fundraising Tradition
When Hollywood bands together for Hand In Hand: A Benefit For Hurricane Harvey Relief on Tuesday night, the entertainers who show up will be participating in a long-running tradition of lending star power to important causes via televised fundraisers. While the comedian Jerry Lewis became the biggest celebrity telethon-er when he started hosting fundraisers for the Muscular Dystrophy Association in the ’50s he wasn’t the first to do one. Comedian Milton Berle is credited with hosting the first telethon, which NBC broadcasted from 12 p.m. on April 9, 1949, to 3:55 a.m. on April 10th. The 16-hour telecast raised ...
Source: TIME.com: Top Science and Health Stories - September 12, 2017 Category: Consumer Health News Authors: Olivia B. Waxman Tags: Uncategorized health photography Television Source Type: news

​Why Sarepta’s latest trial data may presage another FDA controversy
One year after scoring one of the most controversial FDA approvals in recent history, Cambridge-based Sarepta Therapeutics may again find itself at the center of a debate over the agency ’s standards with a new experimental drug. Sarepta (Nasdaq: SRPT) on Wednesday unveiled data from a small, early-stage trial of one of its potential treatments for Duchenne muscular dystrophy, a genetic disorder in which the absence of a protein called dystrophin causes progressive muscle weaknes s. According to… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 6, 2017 Category: Health Management Authors: Max Stendahl Source Type: news

​Why Sarepta’s latest trial data may presage another FDA controversy
One year after scoring one of the most controversial FDA approvals in recent history, Cambridge-based Sarepta Therapeutics may again find itself at the center of a debate over the agency ’s standards with a new experimental drug. Sarepta (Nasdaq: SRPT) on Wednesday unveiled data from a small, early-stage trial of one of its potential treatments for Duchenne muscular dystrophy, a genetic disorder in which the absence of a protein called dystrophin causes progressive muscle weaknes s. According to… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 6, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

New understanding of how muscles work
(McGill University) Muscle malfunctions may be as simple as a slight strain after exercise or as serious as heart failure and muscular dystrophy. A new technique developed at McGill University now makes it possible to look much more closely at how sarcomeres, the basic building blocks within all skeletal and cardiac muscles, work together. It's a discovery that should advance research into a wide range of muscle malfunctions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 23, 2017 Category: International Medicine & Public Health Source Type: news

The King of Comedy, Jerry Lewis Dies at 91 - AARP
5 hours ago ... Comedian Jerry Lewis, known for his unique brand of comedy and his work with the Muscular Dystrophy Association, passed away in Las  ... (Source: AARP.org News)
Source: AARP.org News - August 22, 2017 Category: American Health Source Type: news

Duchenne Action Month Needs YOU!
This September, we are asking you, our community, to participate in Duchenne Action Month in order to create awareness, raise money, and make an impact in the fight to #endDuchenne. Check out 10 simple and powerful actions you can take to make an impact this September: www.parentprojectmd.org/actionmonth (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 22, 2017 Category: Neurology Source Type: news

[Webinar] Gene Therapy for Duchenne - August 2017
Last week, PPMD hosted a webinar focused on understanding the different therapies that are being developed that are commonly referred to as gene therapy, including micro-dystrophin and CRISPR/Cas9, how are they similar and different, and what are the challenges and limitations for each of them. If you missed it, the recording of the webinar is now available! COMING SOON: This fall PPMD will be hosting additional webinars with companies and institutions who are developing gene therapies and/or CRISPR/Cas9 for Duchenne. Stay tuned for more details! (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 22, 2017 Category: Neurology Source Type: news

How You Can Participate in the Ataluren Ad Comm
The FDA has announced the scheduling of a September 28th Advisory Committee Meeting for PTC ’s therapy ataluren. Whether submitting written testimony and/or attending the Ad Comm in person, there are multiple ways for Duchenne community members in the U.S. and abroad to have an impact and share your personal experience with the Advisory Committee reviewing this product. Visit our blog to learn how you can participate. (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 22, 2017 Category: Neurology Source Type: news

Comic and Telethon Host Jerry Lewis Dies At 91
The legendary actor and comedian helped raise more than $2 billion for muscular dystrophy. (Source: WebMD Health)
Source: WebMD Health - August 21, 2017 Category: Consumer Health News Source Type: news

PPMD's Bone Health Workshop Published
Bone health has long been a confusing and often neglected aspect of Duchenne care. There is very little knowledge of underlying bone health in Duchenne, which is further complicated by the possible effects of glucocorticoids on both bone development and bone density/strength. We applaud the incredible work of this group of experts who participated in PPMD's Bone Health Workshop, and hope that, with increased awareness, further work to prevent osteoporosis and enhance bone health in people living with Duchenne will continue. (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 18, 2017 Category: Neurology Source Type: news

PPMD's Every Single [One] Tour: Charleston, WV
Registration for the next stop on PPMD's Every Single [One] Tour is now open! Combining each of the pillars that make up PPMD's mission -- To #EndDuchenne -- the Every Single [One] Tour brings free day-long meetings featuring updates on research, advocacy, and care to the Duchenne community across the country. We hope to see you in Charleston, WV on September 9! (Source: Parent Project Muscular Dystrophy)
Source: Parent Project Muscular Dystrophy - August 17, 2017 Category: Neurology Source Type: news